facebook-script

Afrezza® is the only ultra rapid-acting inhaled insulin available on the market. Afrezza was developed by MannKind Corporation, and continues to be manufactured at the company’s headquarters in Danbury, Connecticut. Many people have asked, is Afrezza discontinued? Definitely not! It was first approved by the FDA in 2014, and remains available by prescription for adults with diabetes mellitus.

Is Afrezza inhaled insulin discontinued?

Afrezza insulin is not discontinued and is available by prescription for adults with type 1 or type 2 diabetes.

Why was Afrezza discontinued?

In 2016, Afrezza was incorrectly rumored to be discontinued after its first year of launch. Manufactured by MannKind Corporation, Afrezza is the only ultra rapid-acting inhaled insulin indicated for adults living with type 1 or type 2 diabetes.

Is Afrezza approved by the FDA?

Afrezza is the only FDA-approved inhaled insulin drug on the market used for the treatment of high blood glucose in adults with type 1 and type 2 diabetes.

Is Afrezza available in the US?

Yes. Afrezza insulin is currently available in the United States for adults living with type 1 or type 2 diabetes via prescription.

*Data for number of Afrezza users treated were calculated from a patient exposure analysis conducted between 2015 and 2021.
US-AFR-1932

Have more questions?

Get more information in our FAQs and
our easy to read Afrezza® A-Z guide

Read more

What is AFREZZA?

Read more

Important Safety Information

What is the most important information I should know about AFREZZA? AFREZZA can cause serious side effects, including:

Sudden lung problems (bronchospasms). In a study, some AFREZZA-treated patients with asthma, whose asthma medication was temporarily withheld, experienced sudden lung problems. Do not use AFREZZA if you have long-term (chronic) lung problems such as asthma or chronic obstructive pulmonary disease (COPD). Before starting AFREZZA, your healthcare provider will give you a breathing test to check how your lungs are working.

 

Important Safety Information(cont’d)

Who should not use Afrezza®?

Do not use Afrezza® if you:

  • Have chronic lung problems such as asthma or COPD.
  • Are allergic to regular human insulin or any of the ingredients in Afrezza®.
  • Are having an episode of low blood sugar (hypoglycemia).

What should I tell my healthcare provider before using Afrezza®?

Before using Afrezza®, tell your healthcare provider about all your medical conditions, including if you:

  • Have lung problems such as asthma or COPD
  • Have or have had lung cancer
  • Are using any inhaled medications
  • Smoke or have recently stopped smoking
  • Have kidney or liver problems
  • Are pregnant, planning to become pregnant, or are breastfeeding. Afrezza® may harm your unborn or breastfeeding baby.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins or herbal supplements.

Before you start using Afrezza®, talk to your healthcare provider about low blood sugar and how to manage it.

What should I avoid while using Afrezza®?

While using Afrezza® do not:

  • Drive or operate heavy machinery, until you know how Afrezza® affects you.
  • Drink alcohol or use over-the-counter medicines that contain alcohol.
  • Smoke.

What are the possible side effects of Afrezza®?

Afrezza® may cause serious side effects that can lead to death, including:

See “What is the most important information I should know about Afrezza®?”

  • Low blood sugar (hypoglycemia). Signs and symptoms that may indicate low blood sugar include:
    • Dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability or mood change, hunger.
  • Decreased lung function. Your healthcare provider should check how your lungs are working before you start using AFREZZA, 6 months after you start using it, and yearly after that.
  • Lung cancer. In studies of Afrezza® in people with diabetes, lung cancer occurred in a few more people who were taking Afrezza® than in people who were taking other diabetes medications. There were too few cases to know if lung cancer was related to Afrezza®. If you have lung cancer, you and your healthcare provider should decide if you should use Afrezza®.
  • Diabetic ketoacidosis. Talk to your healthcare provider if you have an illness. Your Afrezza® dose or how often you check your blood sugar may need to be changed.
  • Severe allergic reaction (whole body reaction). Get medical help right away if you have any of these signs or symptoms of a severe allergic reaction:
    • A rash over your whole body, trouble breathing, a fast heartbeat, or sweating.
  • Low potassium in your blood (hypokalemia).
  • Heart failure. Taking certain diabetes pills called thiazolidinediones or “TZDs” with Afrezza® may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure it may get worse while you take TZDs with Afrezza®. Your healthcare provider should monitor you closely while you are taking TZDs with Afrezza®. Tell your healthcare provider if you have any new or worse symptoms of heart failure including:
    • Shortness of breath, swelling of your ankles or feet, sudden weight gain.

Treatment with TZDs and Afrezza® may need to be changed or stopped by your healthcare provider if you have new or worse heart failure.

Get emergency medical help if you have:

• Trouble breathing, shortness of breath, fast heartbeat, swelling of your face, tongue, or throat, sweating, extreme drowsiness, dizziness, confusion.

The most common side effects of Afrezza® include:

  • Low blood sugar (hypoglycemia), cough, sore throat

These are not all the possible side effects of Afrezza®. Call your doctor for medical advice about side effects.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088 (1-800-332-1088).

Please See Full Prescribing Information, including BOXED WARNING, Medication Guide and Instructions for Use for AFREZZA.


AFREZZA, the Afrezza logo, AFREZZAASSIST, AFREZZAASSIST and logo, MANNKIND, and BLUHALE VIS are registered trademarks of MannKind Corporation. © 2024 MannKind Corporation.
This site is intended for use by U.S. residents only.